Biomedical Engineering Reference
In-Depth Information
estrogen and progesterone receptors in breast cancer.
J Oncol Pract
6
,
195-197 (2010).
26. McShane, L.M.,
et al.
Reporting recommendations for tumor marker
prognostic studies.
J Clin Oncol
23
, 9067-9072 (2005).
27. Kummar, S.,
Compressing drug development timelines in oncology
using phase '0' trials.
et al.
Nat Rev Cancer
7
, 131-139 (2007).
28. Yang, S.X.,
Immunohistochemical detection of poly(ADP-ribose)
polymerase inhibition by ABT-888 in patients with refractory solid
tumors and lymphomas.
et al.
Cancer Biol Ther
8
, 2004-2009 (2009).
29. Wedam, S.B.,
Antiangiogenic and antitumor effects of bevacizumab
in patients with inflammatory and locally advanced breast cancer.
et al.
J
, 769-777 (2006).
30. Rubinstein, L., Crowley, J., Ivy, P., Leblanc, M., and Sargent, D. Randomized
phase II designs.
Clin Oncol
24
, 1883-1890 (2009).
31. Wolff, A.C., and Davidson, N.E. Use of SERMs for the adjuvant therapy of
early-stage breast cancer.
Clin Cancer Res
15
Ann N Y Acad Sci
949
, 80-88 (2001).
32. Slamon, D.J.,
Studies of the HER-2/neu proto-oncogene in human
breast and ovarian cancer.
et al.
Science
244
, 707-712 (1989).
33. Dybdal, N.,
et al.
Determination of HER2 gene amplification by
fluorescence
hybridization and concordance with the clinical
trials immunohistochemical assay in women with metastatic breast
cancer evaluated for treatment with trastuzumab.
in situ
Breast Cancer Res
, 3-11 (2005).
drugsatfda_docs/label/2010/103792s5256lbl.pdf.
fda.gov/drugsatfda_docs/label/2008/021588s024lbl.pdf.
36. Gerber, D.E., and Minna, J.D. ALK inhibition for non-small cell lung
cancer: from discovery to therapy in record time.
Treat
93
Cancer Cell
18
, 548-
551 (2010).
37. Choi, Y.L.,
EML4-ALK mutations in lung cancer that confer
resistance to ALK inhibitors.
et al.
N Engl J Med
363
, 1734-1739 (2010).
38. Kwak, E.L.,
et al.
Anaplastic lymphoma kinase inhibition in non-small-
cell lung cancer.
N Engl J Med
363
, 1693-1703 (2010).
39. Bollag, G.,
Clinical efficacy of a RAF inhibitor needs broad target
blockade in BRAF-mutant melanoma.
et al.
Nature
467
, 596-599 (2010).
40. Flaherty, K.T.,
et al.
Inhibition of mutated, activated BRAF in metastatic
melanoma.
N Engl J Med
363
, 809-819 (2010).
